Direxion Daily S&P Biotech Bear 3X ETF (LABD)
24.95
-1.09 (-4.19%)
USD |
Apr 13, 20:00
Price Chart
Key Stats
Customize
| Expense Ratio | Discount or Premium to NAV | Total Assets Under Management | 30-Day Average Daily Volume |
|---|---|---|---|
| 1.07% | 0.21% | 69.71M | 3.767M |
| Dividend Yield | Turnover Ratio | 1 Year Fund Level Flows | Max Drawdown (All) |
| 0.00% | 0.00% | 210.78M | Upgrade |
Basic Info
| Investment Strategy | |
| The investment seeks daily investment results, before fees and expenses, of 300% of the inverse of the daily performance of the S&P Biotechnology Select Industry Index. The fund, under normal circumstances, invests in swap agreements, futures contracts, short positions or other financial instruments that, in combination, provide inverse (opposite) or short leveraged exposure to the index equal to at least 80% of the fund's net assets (plus borrowing for investment purposes). The index is designed to measure the performance of the biotechnology sub-industry based on the Global Industry Classification Standards ("GICS"). The fund is non-diversified. |
| General | |
| Security Type | Exchange-Traded Fund |
| Equity Style | -- |
| Fixed Income Style | -- |
| Broad Asset Class | Alternative |
| Broad Category | Alternative |
| Category Name | Trading--Inverse Equity |
| Category Index | S&P 500 TR USD |
| Prospectus Objective | Specialty - Technology |
| Fund Owner Firm Name | Direxion Funds |
| Prospectus Benchmark Index | |
| S&P Biotechnology Select Industry TR USD | -300.0% |
| Broad Asset Class Benchmark Index | |
| ^MSACWINTR | 100.0% |
| Manager Tenure | |
| Paul Brigandi | 5.85 yrs |
| Tony Ng | 5.51 yrs |
Net Fund Flows Versus Category
1 Month
% Rank:
--
--
Category Low
--
Category High
1 Year
% Rank:
17
210.78M
-249.84M
Category Low
2.454B
Category High
3 Months
% Rank:
--
--
Category Low
--
Category High
3 Years
% Rank:
--
--
Category Low
--
Category High
6 Months
% Rank:
--
--
Category Low
--
Category High
5 Years
% Rank:
--
--
Category Low
--
Category High
YTD
% Rank:
--
--
Category Low
--
Category High
10 Years
% Rank:
--
--
Category Low
--
Category High
As of March 31, 2021
Performance Versus Category
As of April 13, 2021. Returns for periods of 1 year and above are annualized.
Annual Total Returns Versus Peers
Edit comparables
As of April 13, 2021.
Asset Allocation
Top 3 Holdings
| Name | % Weight | Price | % Change |
|---|---|---|---|
| Goldman Sachs FS Treasury Intms Instl | 58.97% | 1.00 | 0.00% |
| Dreyfus Government Secs Cash Mgmt Admin | 20.34% | 1.00 | 0.00% |
|
S&P Biotechnology Select Industry Index Swap
|
-23.29% | -- | -- |
News
Headline
Wire
Time (ET)
Basic Info
| Investment Strategy | |
| The investment seeks daily investment results, before fees and expenses, of 300% of the inverse of the daily performance of the S&P Biotechnology Select Industry Index. The fund, under normal circumstances, invests in swap agreements, futures contracts, short positions or other financial instruments that, in combination, provide inverse (opposite) or short leveraged exposure to the index equal to at least 80% of the fund's net assets (plus borrowing for investment purposes). The index is designed to measure the performance of the biotechnology sub-industry based on the Global Industry Classification Standards ("GICS"). The fund is non-diversified. |
| General | |
| Security Type | Exchange-Traded Fund |
| Equity Style | -- |
| Fixed Income Style | -- |
| Broad Asset Class | Alternative |
| Broad Category | Alternative |
| Category Name | Trading--Inverse Equity |
| Category Index | S&P 500 TR USD |
| Prospectus Objective | Specialty - Technology |
| Fund Owner Firm Name | Direxion Funds |
| Prospectus Benchmark Index | |
| S&P Biotechnology Select Industry TR USD | -300.0% |
| Broad Asset Class Benchmark Index | |
| ^MSACWINTR | 100.0% |
| Manager Tenure | |
| Paul Brigandi | 5.85 yrs |
| Tony Ng | 5.51 yrs |
Fundamentals
| General | |
| Distribution Yield | Upgrade |
| Dividend Yield TTM (4-13-21) | 0.00% |
| 30-Day SEC Yield | -- |
| 7-Day SEC Yield | -- |
| Number of Holdings | Upgrade |
| Stock | |
| Weighted Average PE Ratio | -- |
| Weighted Average Price to Sales Ratio | -- |
| Weighted Average Price to Book Ratio | -- |
| Weighted Median ROE | -- |
| Weighted Median ROA | -- |
| Forecasted Dividend Yield | -- |
| Forecasted PE Ratio | -- |
| Forecasted Price to Sales Ratio | -- |
| Forecasted Price to Book Ratio | -- |
As of April 12, 2021
Growth Estimates
| Forecasted 5 Yr Earnings Growth | -- |
| Forecasted Book Value Growth | -- |
| Forecasted Cash Flow Growth | -- |
| Forecasted Earnings Growth | -- |
| Forecasted Revenue Growth | -- |
As of April 12, 2021
Fund Details
| Key Dates | |
| Inception Date | 5/28/2015 |
| Last Annual Report Date | 10/31/2020 |
| Last Prospectus Date | 2/28/2021 |
| Attributes | |
| Enhanced Index Fund | No |
| Index Fund |
|
| Inverse Fund |
|
| Leveraged Fund |
|
| Fund of Funds | No |
| Currency Hedged Fund | No |
| Synthetic Replication Fund | No |
| Has Dividend Investment Plan | No |
| Socially Responsible Fund | No |
News
Headline
Wire
Time (ET)